Transcatheter Aortic-Valve Replacement in Low-Risk Patients at Seven Years
Source: View publication →
The 7-year follow-up of the PARTNER 3 trial demonstrates that transcatheter aortic-valve replacement (TAVR) with a balloon-expandable valve is noninferior to surgical aortic-valve replacement (SAVR) in low-risk patients with severe symptomatic aortic stenosis, with no significant differences in clinical outcomes or valve durability.
Key Findings
Study Design
Study Limitations
Clinical Significance
These long-term findings reinforce TAVR as a durable and safe alternative to surgery in low-risk patients with severe aortic stenosis, validating the expansion of TAVR indications into younger, lower-risk demographics previously reserved for SAVR.
Historical Context
The PARTNER trials revolutionized the management of aortic stenosis by sequentially testing TAVR in inoperable, high-risk, intermediate-risk, and finally low-risk patients. The initial 2019 PARTNER 3 results demonstrated superiority for TAVR at 1 year, and this 7-year data provides the necessary long-term evidence regarding structural valve durability that was previously lacking for this low-risk population.
Guided Discussion
High-yield insights from every perspective
How does the mechanical deployment of a balloon-expandable TAVR valve differ from the surgical replacement process (SAVR), and why does this increase the risk of paravalvular regurgitation compared to the surgical approach?
Key Response
In SAVR, the surgeon debrides the calcified native valve leaflets and sutures a prosthetic ring directly to the annulus, creating a tight seal. In TAVR, the native valve is not removed but is instead crushed against the aortic wall by the expanding stent frame. This often results in an imperfect seal, especially if the calcification is eccentric or heavy, leading to paravalvular leak (PVL), which is a key hemodynamic complication monitored in long-term studies like PARTNER 3.
Based on the PARTNER 3 7-year results, which specific clinical and anatomical factors should still lead a heart team to recommend SAVR over TAVR in a low-risk patient?
Key Response
While TAVR was noninferior at 7 years, SAVR remains preferred for patients with bicuspid aortic valves (who were excluded from PARTNER 3), those with heavy LVOT calcification, multi-vessel CAD requiring bypass, or very young patients (e.g., <65 years) where the 'lifetime management' strategy might prioritize a surgical valve first to facilitate easier future TAVR (TAV-in-SAV) or avoid early pacemaker dependency.
The PARTNER 3 7-year data shows a 'catch-up' phenomenon where the initial TAVR advantage in the primary composite endpoint (death, stroke, or rehospitalization) narrows over time. What physiological or valve-related factors might explain this late convergence of the Kaplan-Meier curves?
Key Response
Early TAVR superiority is driven by the avoidance of surgical trauma (sternotomy, bypass). However, over time, the long-term consequences of subclinical leaflet thrombosis, mild paravalvular leaks, and the higher incidence of new permanent pacemaker requirements in TAVR cohorts may lead to increased late-term heart failure or mortality, potentially offsetting the early procedural benefits compared to the durable hemodynamics of a surgical bioprosthesis.
Given that the 7-year data confirms noninferiority but shows no difference in structural valve deterioration (SVD), how should this change the 'shared decision-making' dialogue regarding the anticipated 'warranty' of a TAVR valve in low-risk patients?
Key Response
The data provides reassurance that balloon-expandable SAPIEN 3 valves do not fail prematurely at a higher rate than surgical valves up to 7 years. This allows clinicians to move from 'theoretical concerns about durability' to 'evidence-based noninferiority,' though the dialogue must remain cautious for patients with a life expectancy exceeding 10-15 years, as the 10-year 'gold standard' surgical benchmark has not yet been matched by the TAVR data.
Scholarly Review
Critical appraisal through the lens of expert reviewers and guideline development
Analyze the potential for 'attrition bias' in the 7-year follow-up of PARTNER 3: How might the differential loss to follow-up and the use of a composite endpoint affect the sensitivity of the trial to detect late-term differences in Structural Valve Deterioration (SVD)?
Key Response
In long-term trials, patients who die or are lost to follow-up cannot be assessed for valve durability. If high-risk patients die early, the remaining cohort may represent a 'survivor bias' where only the best-performing valves are measured. Additionally, composite endpoints can be dominated by rehospitalizations, which are more frequent than SVD events, potentially masking a statistically significant difference in actual valve failure rates unless specifically powered for individual components.
The PARTNER 3 investigators report noninferiority at 7 years, yet the numeric incidence of death and stroke was slightly higher in the TAVR group between years 5 and 7. As a reviewer, what additional data on Bioprosthetic Valve Dysfunction (BVD) according to VARC-3 criteria would you require before endorsing the claim that TAVR is equivalent to SAVR for the long term?
Key Response
Editors look for rigorous adherence to standardized definitions. While the study uses VARC-2, the updated VARC-3 criteria provide more granular distinctions between hemodynamic dysfunction and structural failure. A reviewer would flag the 'catch-up' in mortality and demand a more detailed analysis of valve hemodynamics (mean gradients and effective orifice areas) over the entire 7-year period to ensure that the noninferiority isn't just a result of a broadly defined composite endpoint.
Current ACC/AHA guidelines provide a Class 1 recommendation for TAVR in patients >65 years. Does the PARTNER 3 7-year data provide sufficient evidence to extend this recommendation to patients <65, or should the age threshold remain based on the 2020 Guideline's emphasis on valve longevity?
Key Response
The 2020 ACC/AHA guidelines (Table 10) emphasize that for patients <65, SAVR is preferred due to the 20-year durability of surgical valves. While PARTNER 3 is encouraging at 7 years, it lacks the 10-20 year data required to match the life expectancy of a 60-year-old. Therefore, the committee would likely maintain the current age threshold but perhaps upgrade the Level of Evidence for the 65-75 age group while awaiting 10-year PARTNER 3 results.
Clinical Landscape
Noteworthy Related Trials
PARTNER 2 Trial
Tested
Transcatheter Aortic-Valve Replacement (TAVR)
Population
Patients with severe aortic stenosis at intermediate surgical risk
Comparator
Surgical Aortic-Valve Replacement (SAVR)
Endpoint
Composite of death or disabling stroke at 2 years
PARTNER 3 Trial
Tested
Transcatheter Aortic-Valve Replacement (TAVR)
Population
Patients with severe aortic stenosis at low surgical risk
Comparator
Surgical Aortic-Valve Replacement (SAVR)
Endpoint
Composite of death, stroke, or rehospitalization at 1 year
Evolut Low Risk Trial
Tested
Transcatheter Aortic-Valve Replacement (TAVR) with self-expanding valve
Population
Patients with severe aortic stenosis at low surgical risk
Comparator
Surgical Aortic-Valve Replacement (SAVR)
Endpoint
Composite of death or disabling stroke at 24 months
Tailored to your role
Want this tailored to you?
Add your specialty or training stage to get role-specific takeaways and more questions.
Personalize this analysis